07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

BDM-E regulatory update

FDA granted Orphan Drug designation to BioDiem's BDM-E to treat retinitis pigmentosa. The synthetic peptide is in preclinical testing for the indication. The company is seeking partners and funding to start Phase I testing. BioDiem...
07:00 , Oct 15, 2007 |  BC Week In Review  |  Clinical News

BDM-E: Phase I/II data

In a double-blind, Russian Phase I/II trial in 188 patients, BDM-E failed to significantly improve central macular thickness after 17 days compared with placebo, the primary endpoint. The compound also failed to reduce macular thickness...
07:00 , May 7, 2007 |  BC Week In Review  |  Clinical News

BDM-E: Completed Phase I/II enrollment

BDM completed enrollment of 192 patients in a double-blind, Russian Phase I/II trial. Patients will receive daily 10 µg doses of subcutaneous BDM-E or placebo for 10 days. BioDiem Ltd. (ASX:BDM), Melbourne, Australia   Product:...
08:00 , Jan 29, 2007 |  BioCentury  |  Product Development

Back-of-the-eye pipeline

Back-of-the-eye pipeline...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Clinical News

BDM-E: Phase I/II data

Data from 15 evaluable patients in a double-blind, placebo-controlled Phase I/II study showed that subcutaneous BDM-E did not cause any adverse effects. BDM-E was administered for 10 days with follow-up at days 17, 40 and...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Clinical News

BDM-E: Phase I/II start

BDM will start this month a placebo-controlled, double-blind, Russian Phase I/II trial in 192 patients with diabetic macula edema. BioDiem Ltd. , Melbourne, Australia   Product: BDM-E   Business: Ophthalmic   Molecular target: NA  ...